BeyondSpring narrows Q1 loss to $2.4M as Plinabulin and ST-01156 advance
BYSI•BeyondSpring’s first-quarter R&D expenses rose 22% to $1.1M, G&A fell 35% to $1.1M, net loss narrowed to $2.4M and cash reached $7.9M at March 31. AACR 2026 data showed Plinabulin enhanced ADC regimen efficacy and tolerability, and SEED’s ST-01156 entered Phase 1 delivering complete tumor eradication in a neuroblastoma model.
1. First-Quarter Financial Highlights
BeyondSpring recorded R&D expenses of $1.1M for Q1 2026, up from $0.9M a year earlier primarily due to increased drug manufacturing activities. G&A expenses fell to $1.1M from $1.7M as personnel and advisory costs declined, resulting in a net loss of $2.4M versus $2.6M in Q1 2025, with cash, cash equivalents and short-term investments totaling $7.9M and discontinued operations reporting a $4.3M loss.
2. Plinabulin Strengthens ADC Regimens
Preclinical data presented at AACR 2026 demonstrated that Plinabulin significantly improved complete response rates, survival outcomes and tolerability when combined with topoisomerase inhibitor–based ADC therapies, also enhancing the CD8+ T cell/Treg ratio to shift the tumor microenvironment toward an immune-active state, supporting its role as a backbone combination agent.
3. SEED ST-01156 Enters Clinical Development
SEED’s novel RBM39 molecular glue degrader ST-01156 advanced into Phase 1 oncology trials with the first dose cohort completed. In vivo neuroblastoma models achieved complete tumor eradication, and MYC overexpression along with CDKN2A/B deletion were identified as predictive biomarkers, highlighting the RITE3™ platform’s precision oncology potential.
